BioCardia, Inc. reported its financial results for the second quarter ended June 30, 2025, on August 11, 2025. The company filed its quarterly report on Form 10-Q with the Securities and Exchange Commission.
The company highlighted significant progress in advancing its autologous CardiAMP cell therapy candidate for heart failure. Active discussions on the approvability of the CardiAMP Cell Therapy System and the anticipated submission for approval of its Helix transendocardial biotherapeutic delivery catheter were noted.
While the summary did not provide specific financial figures, the company's prior reports indicated consistent net losses and negative operating cash flows. The ability to secure additional funding remains a critical factor for the company's continued operations.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.